Holen Sie sich die Stockscreener-App
33.03
1.46%
-0.1541
Schlusskurs vom Vortag:
$32.88
Offen:
$33.43
24-Stunden-Volumen:
7,418
Relative Volume:
0.03
Marktkapitalisierung:
$941.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.91M
KGV:
-13.43
EPS:
-2.46
Netto-Cashflow:
-
1W Leistung:
+5.92%
1M Leistung:
+20.27%
6M Leistung:
+108.90%
1J Leistung:
+0.00%
1-Tages-Spanne:
$32.03
$33.43
1-Wochen-Bereich:
$30.46
$33.43
52-Wochen-Spanne:
$13.36
$33.47
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
32.82 | 942.85M | 0 | -56.91M | 0 | -2.46 |
VRTX
Vertex Pharmaceuticals Inc
|
426.24 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.29 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.67 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
302.60 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
Jennison Associates LLC Acquires 82,812 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX LB Pharmaceuticals posts slightly smaller Q4 2025 loss than analyst estimates, shares rise 3.66 percent.Community Sell Signals - Newser
LBRX News Today | Why did LB Pharmaceuticals stock go down today? - MarketBeat
Equities Analysts Offer Predictions for LBRX Q1 Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading 5.6% HigherTime to Buy? - MarketBeat
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright & Co. initiates coverage of LB Pharmaceuticals (LBRX) with buy recommendation - MSN
Biopharma breaks its lengthy IPO drought - MSN
Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST) - The Globe and Mail
[ARS] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
Executive pay, board elections lead LB Pharmaceuticals (LBRX) 2026 proxy - Stock Titan
LB Pharmaceuticals (LBRX) Business Model Review | LB Pharmaceuticals Beats EPS Estimates With Narrower LossRecovery Stocks - Cổng thông tin điện tử Tỉnh Sơn La
LBRX (LB Pharmaceuticals Inc) shares jump 9.6% after Q4 2025 EPS edges past consensus analyst estimates. - Xã Thanh Hà
LB Pharmaceuticals publishes phase 2 schizophrenia trial results By Investing.com - Investing.com India
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LBRX (LB Pharmaceuticals Inc) reports narrow Q4 2025 EPS beat but shares fall 2.88 percent in today’s trading.Trending Momentum Stocks - UBND thành phố Hải Phòng
LB Pharmaceuticals publishes phase 2 schizophrenia trial results - Investing.com
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia - ChartMill
LB Pharmaceuticals Inc Common Stock (LBRX) Competitors - Meyka
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know - TipRanks
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 4.5%Should You Sell? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
[EFFECT] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) files resale prospectus for 4.78M shares - Stock Titan
Craig Hallum Initiates Coverage on LB Pharmaceuticals (NASDAQ:LBRX) - Defense World
LBRX Upgraded to Buy by Craig-Hallum on April 10, 2026 - Meyka
Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating - Investing.com UK
Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Craig Hallum - MarketBeat
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference - Bitget
Is LB Pharmaceuticals (LBRX) Stock Overpriced Now | Price at $25.67, Down 1.19%Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 6.1%Here's What Happened - MarketBeat
Investors to resell 4.78M LB Pharmaceuticals (Nasdaq: LBRX) shares - Stock Titan
Is LB Pharmaceuticals (LBRX) Stock Consolidating | Price at $25.44, Down 0.97%Quote Data - Newser
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):